Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2021

Open Access 01-12-2021 | Diabetes | Review

Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis

Authors: Rebuma Belete, Zerihun Ataro, Ahmedmenewer Abdu, Merga Sheleme

Published in: Diabetology & Metabolic Syndrome | Issue 1/2021

Login to get access

Abstract

Background

The presence of metabolic syndrome among diabetes patients is frequent and is associated with an increased incidence of chronic complications and mortality. Despite several studies have been conducted, there is no overall estimation on the prevalence of metabolic syndrome among type 1 diabetic patients. Therefore, this study aimed to estimate the pooled prevalence of metabolic syndrome among patients with type 1 diabetes mellitus.

Methods

Medline via PubMed, CINAHL, ScienceDirect, Ovid, Google Scholar, ResearchGate and African Journals Online were searched by limiting publication period from January 2005 to October 2020. Data were extracted with a standardized format prepared in Microsoft Excel and exported to Stata 16.0 for analyses. The I2 statistic was used to check heterogeneity across the included studies. DerSimonian and Laird random-effects model was applied to estimate pooled prevalence and 95% confidence interval across studies. Funnel plot symmetry, Begg’s test and Egger’s regression test were used to determine the presence of publication bias. Subgroup and sensitivity analysis as well as meta-regression were conducted to explore the potential sources of heterogeneity. The study protocol is registered on PROSPERO with reference number: CRD42020213435.

Results

In this meta-analysis, a total of 27 studies with 45,811 study participants were included. The pooled prevalence of metabolic syndrome was 23.7% with substantial heterogeneity (I2 = 98.2%; P < 0.001). Geographical-based subgroup analysis revealed that the highest prevalence was observed in Australia (27.3%). As per meta-analysis of 17 studies, the pooled prevalence of metabolic syndrome in female type 1 diabetes patients (25.9%) was slightly higher than male T1DM patients (22.5%).

Conclusion

Nearly a quarter of the type 1 diabetes mellitus patients were affected by metabolic syndrome. Therefore, more attention should be paid to the prevention and control of the epidemic and for the reduction of the morbidity and mortality associated with metabolic syndrome among type 1 diabetes mellitus patients.
Appendix
Available only for authorised users
Literature
1.
go back to reference Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.PubMedCrossRef Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition: a consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469–80.PubMedCrossRef
2.
go back to reference Mccracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20.PubMedCrossRef Mccracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol. 2018;36(1):14–20.PubMedCrossRef
3.
go back to reference Cankurtaran M, Halil M, Balam B, Dagli N. Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr. 2006;42:35–45.PubMedCrossRef Cankurtaran M, Halil M, Balam B, Dagli N. Prevalence and correlates of metabolic syndrome (MS) in older adults. Arch Gerontol Geriatr. 2006;42:35–45.PubMedCrossRef
4.
go back to reference Chillarón JJ, Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181–7.PubMedCrossRef Chillarón JJ, Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism. 2014;63(2):181–7.PubMedCrossRef
5.
go back to reference Li X, Cao C, Tang X, Yan X, Zhou H, Liu J, Ji L, Yang X, Zhou Z. Prevalence of metabolic syndrome and its determinants in newly-diagnosed adult-onset diabetes in China: a multi-center, cross-sectional survey. Front Endocrinol. 2019;10:661.CrossRef Li X, Cao C, Tang X, Yan X, Zhou H, Liu J, Ji L, Yang X, Zhou Z. Prevalence of metabolic syndrome and its determinants in newly-diagnosed adult-onset diabetes in China: a multi-center, cross-sectional survey. Front Endocrinol. 2019;10:661.CrossRef
6.
go back to reference Sarafidis PA, Nilsson PM. The metabolic syndrome : a glance at its history. J Hypertens. 2006;24:621–6.PubMedCrossRef Sarafidis PA, Nilsson PM. The metabolic syndrome : a glance at its history. J Hypertens. 2006;24:621–6.PubMedCrossRef
7.
go back to reference Chillarón JJ, Flores-le-roux JA, Goday A, Benaiges D, Carrera MJ. Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol. 2010;63(4):423–9.PubMedCrossRef Chillarón JJ, Flores-le-roux JA, Goday A, Benaiges D, Carrera MJ. Metabolic syndrome and type-1 diabetes mellitus: prevalence and associated factors. Rev Esp Cardiol. 2010;63(4):423–9.PubMedCrossRef
8.
go back to reference Soliman HM, Mosaad YO, Ibrahim A. The prevalence and the clinical profile of metabolic syndrome in children and adolescents with type 1 diabetes. Diabetes Metab Syndr Clin Res Rev. 2019;13:1723–6.CrossRef Soliman HM, Mosaad YO, Ibrahim A. The prevalence and the clinical profile of metabolic syndrome in children and adolescents with type 1 diabetes. Diabetes Metab Syndr Clin Res Rev. 2019;13:1723–6.CrossRef
9.
go back to reference Consultation WHO. Definition, diagnosis, and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999. Consultation WHO. Definition, diagnosis, and classification of diabetes mellitus and its complications. Geneva: World Health Organization; 1999.
10.
go back to reference Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–3.PubMedCrossRef Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16:442–3.PubMedCrossRef
11.
go back to reference National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection. Circulation. 2002;106:3143–421.CrossRef National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection. Circulation. 2002;106:3143–421.CrossRef
12.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005;112:2735–52.PubMedCrossRef
14.
go back to reference Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–5.PubMedCrossRef
15.
go back to reference Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(101):1–9. Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region: a systematic review. BMC Public Health. 2017;17(101):1–9.
16.
go back to reference do Vale Moreira NC, Hussain A, Bhowmik B, Mdala I, Siddiquee T, Fernandes VO, Jay RM, Meyer HE. Prevalence of metabolic syndrome by different definitions, and its association with type 2 diabetes, pre-diabetes, and cardiovascular disease risk in Brazil. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1217–24.CrossRef do Vale Moreira NC, Hussain A, Bhowmik B, Mdala I, Siddiquee T, Fernandes VO, Jay RM, Meyer HE. Prevalence of metabolic syndrome by different definitions, and its association with type 2 diabetes, pre-diabetes, and cardiovascular disease risk in Brazil. Diabetes Metab Syndr Clin Res Rev. 2020;14(5):1217–24.CrossRef
17.
go back to reference Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab Syndr Relat Disord. 2013;11(2):71–80.PubMedCrossRef Friend A, Craig L, Turner S. The prevalence of metabolic syndrome in children: a systematic review of the literature. Metab Syndr Relat Disord. 2013;11(2):71–80.PubMedCrossRef
18.
go back to reference Tan MC, Ng OC, Wong TW, Joseph A, Chan Y, AR Hejar. Prevalence of metabolic syndrome in type 2 diabetic patients: a comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions. Health. 2013;(2013). Tan MC, Ng OC, Wong TW, Joseph A, Chan Y, AR Hejar. Prevalence of metabolic syndrome in type 2 diabetic patients: a comparative study using WHO, NCEP ATP III, IDF and Harmonized definitions. Health. 2013;(2013).
19.
go back to reference Łuczyński W, Szypowska A, Głowińska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. Eur J Pediatr. 2011;170:891–8.PubMedCrossRef Łuczyński W, Szypowska A, Głowińska-Olszewska B, Bossowski A. Overweight, obesity and features of metabolic syndrome in children with diabetes treated with insulin pump therapy. Eur J Pediatr. 2011;170:891–8.PubMedCrossRef
20.
go back to reference Ahola AJ, Harjutsalo V, Thorn LM, Freese R, Forsblom C, Mäkimattila S, et al. The association between macronutrient intake and the metabolic syndrome and its components in type 1 diabetes. Br J Nutr. 2017;117(3):450–6.PubMedCrossRef Ahola AJ, Harjutsalo V, Thorn LM, Freese R, Forsblom C, Mäkimattila S, et al. The association between macronutrient intake and the metabolic syndrome and its components in type 1 diabetes. Br J Nutr. 2017;117(3):450–6.PubMedCrossRef
21.
go back to reference Gingras V, Leroux C, Fortin A, Legault L, Rabasa-lhoret R. Predictors of cardiovascular risk among patients with type 1 diabetes: a critical analysis of the metabolic syndrome and its components. Diabetes Metab. 2017;43(3):217–22.PubMedCrossRef Gingras V, Leroux C, Fortin A, Legault L, Rabasa-lhoret R. Predictors of cardiovascular risk among patients with type 1 diabetes: a critical analysis of the metabolic syndrome and its components. Diabetes Metab. 2017;43(3):217–22.PubMedCrossRef
22.
go back to reference Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols ( PRISMA-P ) 2015 statement. Syst Rev. 2015;4(1):1–9.PubMedPubMedCentralCrossRef Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols ( PRISMA-P ) 2015 statement. Syst Rev. 2015;4(1):1–9.PubMedPubMedCentralCrossRef
24.
go back to reference Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef
26.
go back to reference Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.PubMedCrossRef Sterne JAC, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119–29.PubMedCrossRef
27.
go back to reference Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1. J Diabetes. 2015;7(3):340–6.PubMedCrossRef Blaslov K, Bulum T, Zibar K, Duvnjak L. Relationship between metabolic syndrome and meal-induced glucagon like peptide-1 response in type 1 diabetic patients1-1. J Diabetes. 2015;7(3):340–6.PubMedCrossRef
28.
go back to reference Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56.PubMedCrossRef Merger SR, Kerner W, Stadler M, Zeyfang A, Jehle P, Müller-Korbsch M, et al. Prevalence and comorbidities of double diabetes. Diabetes Res Clin Pract. 2016;119:48–56.PubMedCrossRef
29.
go back to reference Barros BSV, Santos DC, Pizarro MH, Gomes LG, Brito M. Type 1 diabetes and non-alcoholic fatty liver disease: when should we be concerned? A nationwide study in Brazil. Nutrients. 2017;9:878.PubMedCentralCrossRef Barros BSV, Santos DC, Pizarro MH, Gomes LG, Brito M. Type 1 diabetes and non-alcoholic fatty liver disease: when should we be concerned? A nationwide study in Brazil. Nutrients. 2017;9:878.PubMedCentralCrossRef
30.
go back to reference Davis TME, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2007;78(3):412–7.PubMedCrossRef Davis TME, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diabetes Res Clin Pract. 2007;78(3):412–7.PubMedCrossRef
31.
go back to reference Huo L, Ji L, Deng W, Shaw JE, Zhang P, Zhao F, et al. Age distribution and metabolic disorders in people with type 1 diabetes in Beijing and Shantou, China: a cross-sectional study. Diabet Med. 2018;35(6):721–8.PubMedCrossRef Huo L, Ji L, Deng W, Shaw JE, Zhang P, Zhao F, et al. Age distribution and metabolic disorders in people with type 1 diabetes in Beijing and Shantou, China: a cross-sectional study. Diabet Med. 2018;35(6):721–8.PubMedCrossRef
32.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type I diabetes: “double diabetes” in the diabetes control and complications trial. Diabetes Care. 2007;30(3):707–12.PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type I diabetes: “double diabetes” in the diabetes control and complications trial. Diabetes Care. 2007;30(3):707–12.PubMedCrossRef
33.
go back to reference Köken ÖY, Kara C. Prevalence of obesity and metabolic syndrome in children with type 1 diabetes: a comparative assessment based on criteria established by the International Diabetes Federation, World Health Organisation and National Cholesterol Education Program. J Clin Res Pediatr Endocrinol. 2020;12(1):55–62.CrossRef Köken ÖY, Kara C. Prevalence of obesity and metabolic syndrome in children with type 1 diabetes: a comparative assessment based on criteria established by the International Diabetes Federation, World Health Organisation and National Cholesterol Education Program. J Clin Res Pediatr Endocrinol. 2020;12(1):55–62.CrossRef
34.
go back to reference Nádas J, Putz Z, Nyi JF, Gaali Z, Gyimesi A, Neuwirth G, et al. Cardiovascular risk factors characteristic for the metabolic syndrome in adult patients with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2009;117:107–12.PubMedCrossRef Nádas J, Putz Z, Nyi JF, Gaali Z, Gyimesi A, Neuwirth G, et al. Cardiovascular risk factors characteristic for the metabolic syndrome in adult patients with type 1 diabetes. Exp Clin Endocrinol Diabetes. 2009;117:107–12.PubMedCrossRef
35.
go back to reference Pambianco G, Costacou T, Trevor JO. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate. Diabetes Care. 2007;30(5):1248–54.PubMedCrossRef Pambianco G, Costacou T, Trevor JO. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate. Diabetes Care. 2007;30(5):1248–54.PubMedCrossRef
36.
go back to reference Riccardo B, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29:2701–7.CrossRef Riccardo B, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29:2701–7.CrossRef
37.
go back to reference Saki F. Prevalence of metabolic syndrome in children with type 1 diabetes in South of Iran. J Compr Ped. 2016;7(3):e37703.CrossRef Saki F. Prevalence of metabolic syndrome in children with type 1 diabetes in South of Iran. J Compr Ped. 2016;7(3):e37703.CrossRef
38.
go back to reference Santos CE, Schrank Y, Kupfer R. Análise crítica dos critérios da OMS, IDF e NCEP para síndrome metabólica em pacientes portadores de diabetes melito tipo 1. Arq Bras Endocrinol Metab. 2009;53(9):1096–102.CrossRef Santos CE, Schrank Y, Kupfer R. Análise crítica dos critérios da OMS, IDF e NCEP para síndrome metabólica em pacientes portadores de diabetes melito tipo 1. Arq Bras Endocrinol Metab. 2009;53(9):1096–102.CrossRef
39.
go back to reference Szadkowska A, Pietrzak I, Szlawska J, Kozera A, Gadzicka A, Młynarski W. Abdominal obesity, metabolic syndrome in type 1 diabetic children and adolescents. Pediatr Endocrinol Diabetes Metab. 2009;15(4):233–9.PubMed Szadkowska A, Pietrzak I, Szlawska J, Kozera A, Gadzicka A, Młynarski W. Abdominal obesity, metabolic syndrome in type 1 diabetic children and adolescents. Pediatr Endocrinol Diabetes Metab. 2009;15(4):233–9.PubMed
40.
go back to reference Valerio G, Iafusco D, Zucchini S, Maffeis C. Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2012;97(1):99–104.PubMedCrossRef Valerio G, Iafusco D, Zucchini S, Maffeis C. Abdominal adiposity and cardiovascular risk factors in adolescents with type 1 diabetes. Diabetes Res Clin Pract. 2012;97(1):99–104.PubMedCrossRef
41.
go back to reference Ghosh S, Collier A, Hair M, Malik I, Elhadd T. Metabolic syndrome in type 1 diabetes. Int J Diabetes Mellit. 2010;2:38–42.CrossRef Ghosh S, Collier A, Hair M, Malik I, Elhadd T. Metabolic syndrome in type 1 diabetes. Int J Diabetes Mellit. 2010;2:38–42.CrossRef
42.
go back to reference Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2020;38:e14376.PubMed Lee AS, Twigg SM, Flack JR. Metabolic syndrome in type 1 diabetes and its association with diabetes complications. Diabet Med. 2020;38:e14376.PubMed
43.
go back to reference McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications. 2008;22(1):18–23.PubMedCrossRef McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter? J Diabetes Complications. 2008;22(1):18–23.PubMedCrossRef
44.
go back to reference Billow A, Anjana RM, Ngai M, Amutha A, Pradeepa R, Jebarani S, et al. Prevalence and clinical profile of metabolic syndrome among type 1 diabetes mellitus patients in southern India. J Diabetes Complicat. 2015;29(5):659–64.CrossRef Billow A, Anjana RM, Ngai M, Amutha A, Pradeepa R, Jebarani S, et al. Prevalence and clinical profile of metabolic syndrome among type 1 diabetes mellitus patients in southern India. J Diabetes Complicat. 2015;29(5):659–64.CrossRef
45.
go back to reference Ferreira-hermosillo A, Ramírez-rentería C, Mendoza-zubieta V, Molina-ayala MA. Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):32.PubMedPubMedCentralCrossRef Ferreira-hermosillo A, Ramírez-rentería C, Mendoza-zubieta V, Molina-ayala MA. Utility of the waist-to-height ratio, waist circumference and body mass index in the screening of metabolic syndrome in adult patients with type 1 diabetes mellitus. Diabetol Metab Syndr. 2014;6(1):32.PubMedPubMedCentralCrossRef
46.
go back to reference Reinehr T, De SG, Toschke M, Andler W. Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach. Arch Dis Child. 2007;92:1067–72.PubMedPubMedCentralCrossRef Reinehr T, De SG, Toschke M, Andler W. Comparison of metabolic syndrome prevalence using eight different definitions: a critical approach. Arch Dis Child. 2007;92:1067–72.PubMedPubMedCentralCrossRef
48.
go back to reference Ferreira-Hermosillo A, Molina-Ayala M, Ramírez-Rentería C, Vargas G, Gonzalez B, Isibasi A, Archundia-Riveros I, Mendoza V. Inflammatory cytokine profile associated with metabolic syndrome in adult patients with type 1 diabetes. J Diabetes Res. 2015;2015:972073.PubMedPubMedCentralCrossRef Ferreira-Hermosillo A, Molina-Ayala M, Ramírez-Rentería C, Vargas G, Gonzalez B, Isibasi A, Archundia-Riveros I, Mendoza V. Inflammatory cytokine profile associated with metabolic syndrome in adult patients with type 1 diabetes. J Diabetes Res. 2015;2015:972073.PubMedPubMedCentralCrossRef
49.
go back to reference Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32:160–4.PubMedPubMedCentralCrossRef Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, Collier D, et al. Metabolic syndrome and autoimmune diabetes: action LADA 3. Diabetes Care. 2009;32:160–4.PubMedPubMedCentralCrossRef
51.
go back to reference Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, et al. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes Metab Res Rev. 2013;29:446–51.PubMedCrossRef Mollo A, Hernandez M, Marsal JR, Esquerda A, Rius F, Blanco-Vaca F, et al. Latent autoimmune diabetes in adults is perched between type 1 and type 2: evidence from adults in one region of Spain. Diabetes Metab Res Rev. 2013;29:446–51.PubMedCrossRef
52.
go back to reference Rodrigues TC, Canani LH, Schvartzman P, Gross JL. Hypertension is the metabolic syndrome component most strongly associated with microvascular complications and coronary artery calcification in Type 1 diabetes. J Endocrinol Invest. 2011;34:e58-63.PubMedCrossRef Rodrigues TC, Canani LH, Schvartzman P, Gross JL. Hypertension is the metabolic syndrome component most strongly associated with microvascular complications and coronary artery calcification in Type 1 diabetes. J Endocrinol Invest. 2011;34:e58-63.PubMedCrossRef
53.
go back to reference Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28(8):2019–24.PubMedCrossRef Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care. 2005;28(8):2019–24.PubMedCrossRef
Metadata
Title
Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis
Authors
Rebuma Belete
Zerihun Ataro
Ahmedmenewer Abdu
Merga Sheleme
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2021
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/s13098-021-00641-8

Other articles of this Issue 1/2021

Diabetology & Metabolic Syndrome 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.